5-Year Follow-Up Of The Safety, Tolerability And Efficacy Of Subcutaneous Trastuzumab For The Adjuvant Treatment Of Her2-Positive Early Breast Cancer. Results From The Safeher Phase Iii Trial

J. Gligorov,X. Pivot, B. Ataseven,M. De Laurentiis,A. Llombart, K.H. Jung, A. Manikhas, H.A. Azim,A. Alexandrou, K. Gupta, L. Herraez-Baranda, N. Tosti, E. Restuccia

BREAST(2021)

引用 0|浏览7
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要